In this retrospective study, to evaluate the potential of CD133 or ALDH1 as a surrogate marker for NAC resistance, we examined the correlation between chemosensitivity to NAC and CD133 or ALDH1 as well as prognosis of patients with breast cancer after NAC treatment. Here, PROM1 is linked to breast carcinoma.